Compare AbbVie Inc (ABBV) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Materials Select Sector SPDR Fund — how do they compare? AbbVie Inc trades at $253.44 (market cap $449.91B), while Materials Select Sector SPDR Fund trades at $50.28. The key difference: AbbVie Inc pays a 2.72% dividend while Materials Select Sector SPDR Fund pays none, and AbbVie Inc is trading nearer its 52-week high, Materials Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ABBV | XLB | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $53.62 |
52-Week Low | $184.85 | $42.23 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
XLB, the State Street Materials Select Sector SPDR ETF, trades at $51.98, down slightly by 0.06% today. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. The ETF, which provides broad exposure to the U.S. materials sector, lacks disclosed fundamental ratios like P/E and P/S in the provided data. Recent news highlights sector interest, with family offices investing $4.8 billion in materials as of May 23, 2026 (Barron's).
The outlook for XLB is supported by sector rotation into materials amid geopolitical shifts and earnings growth potential, but risks include sensitivity to macroeconomic factors and inflation. Analyst sentiment is mixed, with some viewing valuations as less compelling after recent gains. The ETF's performance will hinge on broader industrial and economic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
